Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced that Dr Christian Homsy, Chief Executive Officer, will present and participate in a panel discussion at the upcoming Stem Cell Meeting on the Mesa being held October 7-9, 2015 in La Jolla, CA, USA.
Dr. Homsy will present during the Partnering Forum event on Wednesday, October 7, 2015 at 11:15 a.m. Pacific Time. He will discuss Celyad’s recent developments, including the Company’s lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure. Additionally, Dr. Homsy will join executives from Cell Therapy Catapult and uniQure NV on a panel entitled “State of the Cell & Gene Therapy Sector in Europe” on Thursday, October 8, 2015 at 9:45 a.m. Pacific Time.
Dr. Christian Homsy, CEO of Celyad, commented, “I am honored to present the Celyad story and participate in this panel at Meeting on the Mesa, one of the preeminent conferences in our industry. I look forward to sharing the details of our ongoing C-Cure and CAR-T cell development programs during our presentation and to sharing the stage with fellow leaders in the European cell therapy field to discuss some of the unique opportunities our companies and industry face.”
Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the Stem Cell Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the regenerative medicine and advanced therapies industry with the scientific community to advance cutting-edge research into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading researchers and clinical experts from around the globe, in conjunction with the industry’s premier annual Partnering Forum, the first and only event of its kind dedicated solely to facilitating connections in this sector. Combined, these meetings attract nearly 800 attendees, fostering key partnerships through more than 500 one-on-one meetings while highlighting the significant clinical and commercial progress in the field over the past year.
